Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Starting Feb. 1, 2026, nitisinone for tyrosinemia type 1 and alkaptonuria will be publicly funded, simplifying access for about 10 patients.
Starting February 1, 2026, Pharmac will fund nitisinone for people with rare disorders tyrosinemia type 1 and alkaptonuria, moving it from the Named Patient Pharmaceutical Assessment to the standard Pharmaceutical Schedule.
This change simplifies access and removes the need for individual applications, benefiting about 10 patients in the first year.
The drug, used with a special diet, helps prevent toxic substance buildup.
Current patients will transition to the LogixX Pharma brand, with alternatives available under Exceptional Circumstances if needed.
Clinicians support the move for improved access and reduced administrative work.
A partir del 1 de febrero de 2026, la nitisinona para la tirosinemia tipo 1 y la alcaptonuria será financiada públicamente, simplificando el acceso para aproximadamente 10 pacientes.